OrbiMed’s Dynavax Technologies DVAX Stock Holding History

OrbiMed’s Portfolio DVAX Stock Details DVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-25,000	Closed	-$275K	–	128
2013 Q2	$275K	Buy	+25,000	New	+$527K	0.01%	127

Other funds holding DVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed's DVAX Position: Q3 2024 in Review

OrbiMed sold out of Dynavax Technologies (DVAX) in Q3 2024, closing a stake of 113,500 shares — an estimated $1.27M sold.

OrbiMed first reported a position in DVAX in Q2 2013 and held it in 9 quarters. The position peaked at $60.7M in Q3 2015. 251 funds tracked by Wall St. Rank hold DVAX as of Q3 2024.

OrbiMed reported no remaining Dynavax Technologies position as of Q3 2024 after selling out during the quarter.
OrbiMed sold 113,500 Dynavax Technologies shares in Q3 2024, an estimated $1.27M.
OrbiMed first reported a position in Dynavax Technologies in Q2 2013 and held it in 9 quarters.
OrbiMed's Dynavax Technologies position peaked at $60.7M in Q3 2015.
251 funds tracked by Wall St. Rank held Dynavax Technologies as of Q3 2024.

Based on OrbiMed's 13F filing for Q3 2024, filed 14 Nov 2024.